NCT07795814Phase 2Recruiting

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

Study sponsor: Edgewise Therapeutics, Inc. · EWTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12Estimated
Enrollment · participants90Estimated
Source updated2026-10-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.